---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-006524"
form_type: "8-K"
ticker: "ACUT"
cik: "0001850767"
company_name: "Accustem Sciences Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:08:18.091431+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AccuStem Sciences appoints Wendy Blosser as CEO with $425k salary and options

## Summary
- Wendy Blosser appointed CEO effective March 4, 2022.
- Base salary of $425,000 per year; eligible for annual bonus of 45% of base, with $47,813 guaranteed in Q1 2022.
- Initial stock option award of 490,000 shares at $2.13 exercise price, subject to board approval.
- 50% of options vest over 4 years; 25% upon $30M equity fundraise; 25% upon CLIA lab launch by Q4 2023.
- Employment is at-will; offer contingent on background check and restrictive covenant agreement.

## SEC filing metadata
- accession: 0001493152-22-006524
- form_type: 8-K
- ticker: ACUT
- cik: 0001850767
- company_name: Accustem Sciences Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850767/000149315222006524/0001493152-22-006524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850767/000149315222006524/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-006524
- JSON: https://secwatch.observer/filing/0001493152-22-006524.json
- Plain text: https://secwatch.observer/filing/0001493152-22-006524.txt

## Key facts
- Executive change
  Wendy Blosser was appointed as Chief Executive Officer at Accustem Sciences Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Pursuant to an agreement dated February 18, 2022 (the “Offer Letter”), Wendy Blosser was appointed Chief Executive Officer of AccuStem Sciences, Inc. effective March 4, 2022 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850767/000149315222006524/0001493152-22-006524-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.